Literature DB >> 27391387

Metabolic Syndrome After HIV Acquisition in South African Women.

Magdalena E Sobieszczyk1, Lise Werner, Koleka Mlisana, Nivashnee Naicker, Addi Feinstein, Clive M Gray, Lindi Masson, Jo-Ann S Passmore, Carolyn Williamson, Quarraisha Abdool Karim, Salim S Abdool Karim, Nigel J Garrett.   

Abstract

BACKGROUND: Noncommunicable diseases are common among chronically infected patients with HIV in the developed world, but little is known about these conditions in African cohorts. We assessed the epidemiology of metabolic syndrome among young South African women during the first 3 years after HIV acquisition.
METHODS: A total of 160 women were followed prospectively in the CAPRISA 002 Acute Infection study. Metabolic syndrome was defined as a constellation of hyperlipidemia, hypertension, hyperglycemia/diabetes, and abdominal obesity. Time trends were assessed using generalized estimation equation models.
RESULTS: Median age was 24 years and body mass index 27 kg/m. Prevalence of metabolic syndrome at infection was 8.7% increasing to 19.2% over 36 months (P = 0.001). The proportion of women with body mass index >30 kg/m increased from 34.4% to 47.7% (P = 0.004), those with abnormal waist circumference and elevated blood pressure increased from 33.5% to 44.3% (P = 0.060) and 23.8% to 43.9% (P < 0.001), respectively. Incidence of metabolic syndrome was 9.13/100 person-years (95% CI: 6.02 to 13.28). Predictors of metabolic syndrome were age (per year increase odds ratio (OR) = 1.12; 95% CI: 1.07 to 1.16), time postinfection (per year OR = 1.47; 95% CI: 1.12 to 1.92), family history of diabetes (OR = 3.13; 95% CI: 1.71 to 5.72), and the human leukocyte antigen (HLA)-B*81:01 allele (OR = 2.95; 95% CI: 1.21 to 7.17), whereas any HLA-B*57 or B*58:01 alleles were protective (OR = 0.34; 95% CI: 0.15 to 0.77). HIV-1 RNA (OR = 0.89; 95% CI: 0.62 to 1.27) and CD4 count (OR = 1.03; 95% CI: 0.95 to 1.11) did not predict metabolic syndrome.
CONCLUSIONS: The high burden of metabolic conditions in young South African HIV-infected women highlights the need to integrate noncommunicable disease and HIV care programs. Interventions to prevent cardiovascular disease must start at HIV diagnosis, rather than later during the disease course.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27391387     DOI: 10.1097/QAI.0000000000001123

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  11 in total

Review 1.  Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation.

Authors:  Avanthi Raghavan; Dodie E Rimmelin; Kathleen V Fitch; Markella V Zanni
Journal:  Curr HIV/AIDS Rep       Date:  2017-12       Impact factor: 5.071

2.  Metabolic Syndrome Among Antiretroviral Therapy-Naive Versus Experienced HIV-Infected Patients Without Preexisting Cardiometabolic Disorders in Western Kenya.

Authors:  Alfred Osoti; Tecla M Temu; Nicholas Kirui; Edmond K Ngetich; Jemima H Kamano; Stephanie Page; Carey Farquhar; Gerald S Bloomfield
Journal:  AIDS Patient Care STDS       Date:  2018-06       Impact factor: 5.078

3.  Intramyocardial Triglycerides Among Women With vs Without HIV: Hormonal Correlates and Functional Consequences.

Authors:  Mabel Toribio; Tomas G Neilan; Magid Awadalla; Lauren A Stone; Adam Rokicki; Corinne Rivard; Connor P Mulligan; Diana Cagliero; Lindsay T Fourman; Takara L Stanley; Jennifer E Ho; Virginia A Triant; Tricia H Burdo; Michael D Nelson; Lidia S Szczepaniak; Markella V Zanni
Journal:  J Clin Endocrinol Metab       Date:  2019-12-01       Impact factor: 5.958

Review 4.  Diabetes, metabolic syndrome and dyslipidemia in people living with HIV in Africa: re-emerging challenges not to be forgotten.

Authors:  Nazik Elmalaika Husain; Sufian K Noor; Wadie M Elmadhoun; Ahmed O Almobarak; Heitham Awadalla; Clare L Woodward; Dushyant Mital; Mohamed H Ahmed
Journal:  HIV AIDS (Auckl)       Date:  2017-11-08

5.  Carbohydrate, lipid, bone and inflammatory markers in HIV-positive adolescents on antiretroviral therapy and hormonal contraception.

Authors:  Nadia Kancheva Landolt; Torsak Bunupuradah; Jullapong Achalapong; Pope Kosalaraksa; Witaya Petdachai; Chaiwat Ngampiyaskul; Sasiwimol Ubolyam; Narukjaporn Thammajaruk; Stephen Kerr; Jintanat Ananworanich
Journal:  J Virus Erad       Date:  2017-01-01

6.  Plasma proteomics reveals markers of metabolic stress in HIV infected children with severe acute malnutrition.

Authors:  Gerard Bryan Gonzales; James M Njunge; Bonface M Gichuki; Bijun Wen; Isabel Potani; Wieger Voskuijl; Robert H J Bandsma; James A Berkley
Journal:  Sci Rep       Date:  2020-07-08       Impact factor: 4.379

7.  Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa-a systematic review and meta-analysis.

Authors:  Olamide O Todowede; Solange Z Mianda; Benn Sartorius
Journal:  Syst Rev       Date:  2019-01-03

8.  Metabolic Control and Determinants Among HIV-Infected Type 2 Diabetes Mellitus Patients Attending a Tertiary Clinic in Botswana.

Authors:  Godfrey Mutashambara Rwegerera; Dorothea H P Shailemo; Yordanka Pina Rivera; Kathryn O Mokgosi; Portia Bale; Taibat Aderonke Oyewo; Bruno Diaz Luis; Dereje Habte; Brian Godman
Journal:  Diabetes Metab Syndr Obes       Date:  2021-01-11       Impact factor: 3.168

Review 9.  Chronic hepatitis B-associated liver disease in the context of human immunodeficiency virus co-infection and underlying metabolic syndrome.

Authors:  Edina Amponsah-Dacosta; Cynthia Tamandjou Tchuem; Motswedi Anderson
Journal:  World J Virol       Date:  2020-12-15

10.  Low-level genital HIV shedding in Thai HIV-infected women with suppressed plasma viral load after menopause: a longitudinal study.

Authors:  Nadia Kancheva Landolt; Tanya Do; Naruporn Kasipong; Rosalin Kriengsinyot; Sasiwimol Ubolyam; Apicha Mahanontharit; Tippawan Pankam; Tanakorn Apornpong; Anchalee Avihingsanon; Jintanat Ananworanich; Nittaya Phanuphak; Surasith Chaithongwongwatthana
Journal:  J Virus Erad       Date:  2017-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.